On ECHEMI
Home > Drugs > Xian Jingxi Double-Crane Pharmaceutical Co., Ltd.
Xian Jingxi Double-Crane Pharmaceutical Co., Ltd.
  • Founded in:

    2002-01-18
  • Country:

    China China
  • Address:

    Gucheng Road, Huyi District, Xi'an
  • Tax NO.:

    91610125221080753H
  • Registered Funds:

    55.4216 million yuan
  • Email:

Related Drugs
Ofloxacin Sodium Chloride Injection
The main ingredient of this product is ofloxacin. Its chemical name is (plusmn;)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7Hpyrido[1,2,3-de]-[1,4]benzo[omicron]oxazine-6-carboxylic acid.
Name Description Content CAS NO. Registered Holders
Ofloxacin

This product has a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic Gram-negative bacilli. It has good antibacterial activity in vitro against the following bacteria: most bacteria of the Enterobacteriaceae family, including Citrobacter, Enterobacter cloacae, Enterobacter aerogenes, Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Vibrio, Yersinia, etc. It often has antibacterial activity against multi-drug resistant bacteria. It has high antibacterial activity against penicillin-resistant Neisseria gonorrhoeae, enzyme-producing Haemophilus influenzae and Moraxella. It has antibacterial activity against most strains of Pseudomonas such as Pseudomonas aeruginosa. This product has antibacterial activity against methicillin-sensitive Staphylococcus aureus, and only moderate antibacterial activity against Streptococcus pneumoniae, hemolytic Streptococcus and Enterococcus faecalis. It has good antimicrobial activity against Chlamydia trachomatis, Mycoplasma, Legionella, and also has antibacterial activity against Mycobacterium tuberculosis and atypical mycobacteria. Poor antibacterial activity against anaerobic bacteria. Ofloxacin is a bactericide that acts on the A subunit of bacterial DNA helicase, inhibiting DNA synthesis and replication, leading to bacterial death.

More

This product has a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic Gram-negative bacilli. It has good antibacterial activity in vitro against the following bacteria: most bacteria of the Enterobacteriaceae family, including Citrobacter, Enterobacter cloacae, Enterobacter aerogenes, Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Vibrio, Yersinia, etc. It often has antibacterial activity against multi-drug resistant bacteria. It has high antibacterial activity against penicillin-resistant Neisseria gonorrhoeae, enzyme-producing Haemophilus influenzae and Moraxella. It has antibacterial activity against most strains of Pseudomonas such as Pseudomonas aeruginosa. This product has antibacterial activity against methicillin-sensitive Staphylococcus aureus, and only moderate antibacterial activity against Streptococcus pneumoniae, hemolytic Streptococcus and Enterococcus faecalis. It has good antimicrobial activity against Chlamydia trachomatis, Mycoplasma, Legionella, and also has antibacterial activity against Mycobacterium tuberculosis and atypical mycobacteria. Poor antibacterial activity against anaerobic bacteria. Ofloxacin is a bactericide that acts on the A subunit of bacterial DNA helicase, inhibiting DNA synthesis and replication, leading to bacterial death.

82419-36-1 30
Pentoxifylline Sodium Chloride Injection
The main ingredient of this product is pentoxifylline, and its chemical name is: 3,7-dihydro-3,7-dimethyl-1-(5-oxohexyl)-1hydrogen-purine-2,6-dione.
Name Description Content CAS NO. Registered Holders
Pentoxifylline

It improves blood rheology by reducing blood viscosity, reduces blood viscosity in a dose-dependent manner, improves red blood cell deformability, improves the blood rheological properties of white blood cells, and inhibits the adhesion and activation of neutrophils. For patients with chronic peripheral arterial vascular disease, it can increase blood flow, affect microcirculation, and improve tissue oxygen supply.

More

It improves blood rheology by reducing blood viscosity, reduces blood viscosity in a dose-dependent manner, improves red blood cell deformability, improves the blood rheological properties of white blood cells, and inhibits the adhesion and activation of neutrophils. For patients with chronic peripheral arterial vascular disease, it can increase blood flow, affect microcirculation, and improve tissue oxygen supply.

6493-05-6 41
Levofloxacin Lactate Injection
Main ingredients and chemical name of this product: The main ingredient of this product is levofloxacin lactate, and its chemical name is: (S)-(-)-9-fluoro-2-,3-dihydro-3-methyl-10(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de][1,4]-benzoxazine-6-carboxylic acid lactate hemihydrate. [Molecular formula] C18H20FN3O4C3H6O31/2H2O [Molecular weight] 460.41
Name Description Content CAS NO. Registered Holders
LEVOFLOXACIN LACTATE

This product is the levorotatory form of ofloxacin, and its antibacterial activity is about 2 times that of ofloxacin. Its main mechanism of action is to inhibit bacterial DNA gyrase activity and inhibit bacterial DNA replication. It has the characteristics of broad antibacterial spectrum and strong antibacterial effect. It has strong antibacterial activity against most Enterobacteriaceae, such as Klebsiella pneumoniae, Proteus, Salmonella typhi, Shigella, influenza bacillus, some Escherichia coli, Pseudomonas aeruginosa, and gonococci; it also has good antibacterial effect against some Staphylococci, Streptococcus pneumoniae, Chlamydia, etc.

More

This product is the levorotatory form of ofloxacin, and its antibacterial activity is about 2 times that of ofloxacin. Its main mechanism of action is to inhibit bacterial DNA gyrase activity and inhibit bacterial DNA replication. It has the characteristics of broad antibacterial spectrum and strong antibacterial effect. It has strong antibacterial activity against most Enterobacteriaceae, such as Klebsiella pneumoniae, Proteus, Salmonella typhi, Shigella, influenza bacillus, some Escherichia coli, Pseudomonas aeruginosa, and gonococci; it also has good antibacterial effect against some Staphylococci, Streptococcus pneumoniae, Chlamydia, etc.

294662-18-3 11
Compound Sodium Acetate Injection
This product is a compound preparation, each 1000ml contains: sodium acetate 12.24g, sodium chloride 11.7g, potassium chloride 0.600g, calcium chloride 0.666g.
Name Description Content CAS NO. Registered Holders
Sodium acetate

Infusion or oral administration of too much or too fast can cause water and sodium retention, resulting in edema, increased blood pressure, increased heart rate, chest tightness, dyspnea, and even acute left heart failure.

More

Infusion or oral administration of too much or too fast can cause water and sodium retention, resulting in edema, increased blood pressure, increased heart rate, chest tightness, dyspnea, and even acute left heart failure.

12.24g 127-09-3 34
Sodium chloride

Infusion or oral administration of too much or too fast can cause water and sodium retention, resulting in edema, increased blood pressure, increased heart rate, chest tightness, dyspnea, and even acute left heart failure.

More

Infusion or oral administration of too much or too fast can cause water and sodium retention, resulting in edema, increased blood pressure, increased heart rate, chest tightness, dyspnea, and even acute left heart failure.

11.7g 7647-14-5 43
Potassium chloride

Infusion or oral administration of too much or too fast can cause water and sodium retention, resulting in edema, increased blood pressure, increased heart rate, chest tightness, dyspnea, and even acute left heart failure.

More

Infusion or oral administration of too much or too fast can cause water and sodium retention, resulting in edema, increased blood pressure, increased heart rate, chest tightness, dyspnea, and even acute left heart failure.

0.600g 7447-40-7 39
Calcium chloride

Infusion or oral administration of too much or too fast can cause water and sodium retention, resulting in edema, increased blood pressure, increased heart rate, chest tightness, dyspnea, and even acute left heart failure.

More

Infusion or oral administration of too much or too fast can cause water and sodium retention, resulting in edema, increased blood pressure, increased heart rate, chest tightness, dyspnea, and even acute left heart failure.

0.666g 10043-52-4 27
Compound Sodium Acetate Injection
This product is a compound preparation, each 1000ml contains: sodium acetate 12.24g, sodium chloride 11.7g, potassium chloride 0.600g, calcium chloride 0.666g.
Name Description Content CAS NO. Registered Holders
Sodium acetate

Excessive or rapid infusion or oral administration can cause water and sodium retention, leading to edema, increased blood pressure, increased heart rate, chest tightness, difficulty breathing, and even acute left heart failure.

More

Excessive or rapid infusion or oral administration can cause water and sodium retention, leading to edema, increased blood pressure, increased heart rate, chest tightness, difficulty breathing, and even acute left heart failure.

12.24g 127-09-3 34
Sodium chloride

Excessive or rapid infusion or oral administration can cause water and sodium retention, leading to edema, increased blood pressure, increased heart rate, chest tightness, difficulty breathing, and even acute left heart failure.

More

Excessive or rapid infusion or oral administration can cause water and sodium retention, leading to edema, increased blood pressure, increased heart rate, chest tightness, difficulty breathing, and even acute left heart failure.

11.7g 7647-14-5 43
Potassium chloride

Excessive or rapid infusion or oral administration can cause water and sodium retention, leading to edema, increased blood pressure, increased heart rate, chest tightness, difficulty breathing, and even acute left heart failure.

More

Excessive or rapid infusion or oral administration can cause water and sodium retention, leading to edema, increased blood pressure, increased heart rate, chest tightness, difficulty breathing, and even acute left heart failure.

0.600g 7447-40-7 39
Calcium chloride

Excessive or rapid infusion or oral administration can cause water and sodium retention, leading to edema, increased blood pressure, increased heart rate, chest tightness, difficulty breathing, and even acute left heart failure.

More

Excessive or rapid infusion or oral administration can cause water and sodium retention, leading to edema, increased blood pressure, increased heart rate, chest tightness, difficulty breathing, and even acute left heart failure.

0.666g 10043-52-4 27
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.